Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Дроспиренон, прогестин с уникальным сердечно-сосудистым профилем, для безопасной контрацепции и лечения менопаузальных симптомов
Дроспиренон, прогестин с уникальным сердечно-сосудистым профилем, для безопасной контрацепции и лечения менопаузальных симптомов
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605–13.
2. Writing Group for Women’s Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321–33.
3. Sitruk-Ware R. Pharmacology of different progestogens: the special case of drospirenone. Climacteric 2005; 8 (Suppl. 3): 4–12.
4. Oelkers WHK. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Climacteric 2005; 8 (Suppl. 3): 19–27.
5. Lobo RA. The rationale for low-dose hormonal therapy. Endocrine 2004; 24: 217–21.
6. Oelkers W. Drospirenone, a progestogen with antimineralocortical properties: a short review. Mol Endocrin Cell Endocrinol 2004; 217: 255–61.
7. Rubig A. Drospirenone: a new cardiovascularactive progestin with antialdosterone and antiandrogenic properties. Climacteric 2003; 6 (Suppl. 3): 49–54.
8. Foidart J.-M. Added benefits of drospirenone for compliance. Climacteric 2005; 8 (Suppl. 3): 28–34.
9. MacGregor GA, He FJ. Importance of controlling blood pressure. Climacteric 2005; 8 (Suppl. 3): 13–8.
10. Christiansen C. Effects of drospirenone/estrogen combinations on bone metabolism. Climacteric 2005; 8 (Suppl. 3): 35–41.
2. Writing Group for Women’s Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321–33.
3. Sitruk-Ware R. Pharmacology of different progestogens: the special case of drospirenone. Climacteric 2005; 8 (Suppl. 3): 4–12.
4. Oelkers WHK. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Climacteric 2005; 8 (Suppl. 3): 19–27.
5. Lobo RA. The rationale for low-dose hormonal therapy. Endocrine 2004; 24: 217–21.
6. Oelkers W. Drospirenone, a progestogen with antimineralocortical properties: a short review. Mol Endocrin Cell Endocrinol 2004; 217: 255–61.
7. Rubig A. Drospirenone: a new cardiovascularactive progestin with antialdosterone and antiandrogenic properties. Climacteric 2003; 6 (Suppl. 3): 49–54.
8. Foidart J.-M. Added benefits of drospirenone for compliance. Climacteric 2005; 8 (Suppl. 3): 28–34.
9. MacGregor GA, He FJ. Importance of controlling blood pressure. Climacteric 2005; 8 (Suppl. 3): 13–8.
10. Christiansen C. Effects of drospirenone/estrogen combinations on bone metabolism. Climacteric 2005; 8 (Suppl. 3): 35–41.
Авторы
O.Ylikorkala
Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms
Climacteric 2005; 8 (Suppl. 3): 1–3.
Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms
Climacteric 2005; 8 (Suppl. 3): 1–3.
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.